2020 Shortlist review

Back | Best Communication Award | Breakthrough of the Year AwardBest Technology Award
Mediscience Commentator of the Year Award | Capital Market Transaction of the Year Award
Most Significant Contribution to the Mediscience Sector AwardThe Emerging Star Award
Chief Executive of the Year AwardCompany of the Year Award 


Company of the Year Award

Sponsored by WG Partners 

Criteria 

The Company of the Year will already have gained recognition by analysts and investors.

It will be a well managed, soundly financed growth business with a well defined strategy to deliver its key financial, ethical and social ambitions. Put simply, the Voting Panel are not necessarily looking for the biggest, but they are looking for the best.

The 2020 finalists:  


EMA20_Shortlist-logo_argenx.png

argenx SE 

www.argenx.com

It’s been an outstanding year for argenx, led by Tim Van Hauwermeiren, who was crowned CEO of the Year at the European Mediscience Awards 2019. The group’s run of success has continued, validated by its triple shortlisting at the awards this year.

During the period, argenx made significant progress towards its 2021 vision of becoming a fully integrated, global immunology company. The group ran five registrational and seven earlier-stage clinical trials, fuelling its ambition to have five product launches in five years, starting in 2021.

argenx’s milestone moment came through its first ever pivotal Phase III ADAPT trial of efgartigimod, for the treatment of myasthenia gravis, a rare and chronic autoimmune disease.  Positive results from the trial were announced just outside the period, in May this year, and the group is now planning to submit to the US FDA.

 

EMA20_Shortlist-logo-Astrazeneca.png

AstraZeneca plc 

www.astrazeneca.co.uk 

AstraZeneca focuses on three main therapy areas: Oncology;  Cardiovascular, Renal and Metabolism (CVRM); and Respiratory, whilst also selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

AstraZeneca has led the way in life sciences in the UK, Europe and beyond, transforming the life sciences landscape and building an ecosystem to support others in the sector. Last year was the first full year of AstraZeneca’s return to Product Sales growth, achieved by transforming its pipeline and focusing on science-led innovation.

AZ has a unique ability to respond to a changing world. This was perfectly demonstrated recently by the group’s agreement to supply, if successful, up to 400m doses of the Covid-19 vaccine developed by the University of Oxford, before the end of 2020.

 

 
EMA20_Shortlist-logo_Galapagos.png

Galapagos NV 

www.glpg.com

Another triple shortlisting for Galapagos, who had a stand-out, historic year. The group’s CEO, Onno Van de Stolpe, has also been nominated for CEO of the year for leading the business through its remarkable year.

In July last year, Galapagos announced it was entering into a 10-year collaboration with Gilead Sciences, worth $5.1bn. The deal gave Gilead access to Galapagos’ six clinical-phase assets, 20 preclinical programs and its future products over the next decade, effectively safeguarding the independence of Galapagos and giving it the ability to mature into a multiproduct, commercial-stage company.

The 20th anniversary year was also significant for Galapagos because, for the first time in the group’s history, a drug candidate from its pipeline is under review for approval. Pending approval, it is now preparing to commercialise filgotinib in partnership with Gilead.

 

Genmab A/S 

www.genmab.com

A record breaking four nominations for Genmab at this year’s awards, reflecting the momentous year the group has had, with breakthroughs achieved in all areas of its business. CEO, Jan van de Winkel was also shortlisted? nominated for CEO of the Year 2020.

During the period, Genmab experienced unprecedented progress in the development of its early-stage proprietary pipeline and also secured multiple new strategic partnerships, including an exclusive worldwide license and option agreement with Janssen. In addition, it was a transformational year for DARZALEX, which is approaching triple-blockbuster status and for ofatumumab, which is being commercialised by Novartis.

The other significant milestone for the business was its NASDAQ IPO in July 2019.This was the second largest US IPO ever achieved by a European biotech and establishes Genmab as a world-class antibody innovation powerhouse. 

 
EMA20_Shortlist-logo_Genmab.png

 
EMA20_Shortlist-image_Breakthrough_Genmab.png